Precede Biosciences

About Precede Biosciences

Precede Biosciences is dedicated to expanding the reach of precision medicine by providing unprecedented resolution into disease-defining biology through a simple blood test. Their mission is to enhance the success rate of new medicine development and ensure minimally invasive, precise diagnoses and treatments tailored to individual disease biology.

Products & Services

Liquid Biopsy Platform:A first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, offering genome-wide insights into the activation of individual genes and pathways to inform therapy selection and drug development.

Specialties

Liquid Biopsy Development Computational Biology Epigenomics Translational Sciences Precision Medicine Cancer Diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 83500000 MR: - FA: 83.5 million FAN: 83500000	D: 2026-01-12 FD: 2026-01-12	12 investors

Series B Latest

2026-01-12

$83.5M

12 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jessica Alfano

Vice President, Head of Legal

LinkedIn (Pro only)

J

J. Carl Barrett

Chief Scientific Officer

LinkedIn (Pro only)

K

Kristian Cibulskis

Vice President, Head of Bioinformatics Engineering

LinkedIn (Pro only)

T

Travis Clark

Vice President, Product Development

M

Matthew Eaton

Vice President, Computational Biology

J

Jennifer Fortune

Chief Operating Officer

View 62 more team members with Pro

Unlock Full Team Directory

Recent News